Myonexus Therapeutics Report issue

For profit Phase 2
Founded: Columbus OH United States (2017)
Status: Acquired by Sarepta Therapeutics (2019)

Organization Overview

First Clinical Trial
2018
NCT03652259
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Myonexus Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

bidridistrogene xeboparvovec (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 2)

Muscular Dystrophies, Limb-Girdle (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1